Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company dedicated to discovering and developing life-changing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company developed and commercializes Ingrezza, a standard-of-care VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington disease. Through clinical research pipelines in central nervous system pharmacology, Neurocrine Biosciences advances therapies for debilitating brain-related conditions.